James Darecca - 05 Aug 2025 Form 4 Insider Report for Prestige Consumer Healthcare Inc. (PBH)

Reporting relationship: Director
Issuer ticker: PBH
Reported as of: 05 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Aug 2025, 16:02:58 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ James C. D'Arecca by Christine Sacco Attorney-in-Fact pursuant to Power of Attorney dated July 5, 2023 on file with the Commission

Key filing fact

James Darecca filed Form 4 for Prestige Consumer Healthcare Inc. (PBH) on 06 Aug 2025.

Key facts

This page summarizes James Darecca's Form 4 filing for Prestige Consumer Healthcare Inc. (PBH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Aug 2025, 16:02.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001583903 Primary reporting owner

DArecca James

Relationship: Director
Address: 660 WHITE PLAINS ROAD, TARRYTOWN
Signature: /s/ James C. D'Arecca by Christine Sacco Attorney-in-Fact pursuant to Power of Attorney dated July 5, 2023 on file with the Commission
Signature date: 06 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PBH transaction

Common Stock, par value $0.01 per share

Award

Transaction value: $0
Shares: +2,094
Change %: +47%
Price: $0.000000
Shares after: 6,591
Date: 05 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person received 2,094 restricted stock units equal to $155,000 divided by the closing stock price of $674.04 on August 5, 2025, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control.